<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001718996</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>COMMON STOCK</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>12/29/2023</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001610820</issuerCik>
        <issuerName>BriaCell Therapeutics Corp.</issuerName>
        <issuerCusip>107930109</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR</com:street1>
          <com:city>WEST VANCOUVER</com:city>
          <com:stateOrCountry>A1</com:stateOrCountry>
          <com:zipCode>V7T 2X1</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(b)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Copia Fund (Cayman) LP</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>E9</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>818375.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>818375.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <classPercent>5.1</classPercent>
      <typeOfReportingPerson>FI</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>BriaCell Therapeutics Corp.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER, BRITISH COLUMBIA, CANADA, V7T 2X1</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>COPIA FUND (CAYMAN) LP</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>103 S. Church St., 2nd Flr., P.O. Box 472
George Town, Grand Cayman KY1-1106
Cayman Islands</principalBusinessOfficeOrResidenceAddress>
        <citizenship>CAYMAN ISLANDS</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>N</notApplicableFlag>
        <typeOfPersonFiling>FI</typeOfPersonFiling>
        <otherTypeOfPersonFiling>CAYMAN ISLANDS REGULATED FUND</otherTypeOfPersonFiling>
      </item3>
      <item4>
        <amountBeneficiallyOwned>818375</amountBeneficiallyOwned>
        <classPercent>5.1</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>818375</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>0</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
        <classOwnership5PercentOrLess>N</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under &amp;#167; 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Copia Fund (Cayman) LP</reportingPersonName>
      <signatureDetails>
        <signature>Adam Lambert</signature>
        <title>General Partner</title>
        <date>01/08/2024</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
